Literature DB >> 24320221

Formulation and characterization of nanoemulsion intranasal adjuvants: effects of surfactant composition on mucoadhesion and immunogenicity.

Pamela T Wong1, Su He Wang, Susan Ciotti, Paul E Makidon, Douglas M Smith, Yongyi Fan, Charles F Schuler, James R Baker.   

Abstract

The development of effective intranasal vaccines is of great interest due to their potential to induce both mucosal and systemic immunity. Here we produced oil-in-water nanoemulsion (NE) formulations containing various cationic and nonionic surfactants for use as adjuvants for the intranasal delivery of vaccine antigens. NE induced immunogenicity and antigen delivery are believed to be facilitated through initial contact interactions between the NE droplet and mucosal surfaces which promote prolonged residence of the vaccine at the site of application, and thus cellular uptake. However, the details of this mechanism have yet to be fully characterized experimentally. We have studied the physicochemical properties of the NE droplet surfactant components and demonstrate that properties such as charge and polar headgroup geometry influence the association of the adjuvant with the mucus protein, mucin. Association of NE droplets with mucin in vitro was characterized by various biophysical and imaging methods including dynamic light scattering (DLS), zeta potential (ZP), and surface plasmon resonance (SPR) measurements as well as transmission electron microscopy (TEM). Emulsion surfactant compositions were varied in a systematic manner to evaluate the effects of hydrophobicity and polar group charge/size on the NE-mucin interaction. Several cationic NE formulations were found to facilitate cellular uptake of the model antigen, ovalbumin (OVA), in a nasal epithelial cell line. Furthermore, fluorescent images of tissue sections from mice intranasally immunized with the same NEs containing green fluorescent protein (GFP) antigen demonstrated that these NEs also enhanced mucosal layer penetration and cellular uptake of antigen in vivo. NE-mucin interactions observed through biophysical measurements corresponded with the ability of the NE to enhance cellular uptake. Formulations that enhanced antigen uptake in vitro and in vivo also led to the induction of a more consistent antigen specific immune response in mice immunized with NEs containing OVA, linking NE-facilitated mucosal layer penetration and cellular uptake to enhancement of the immune response. These findings suggest that biophysical measurement of the mucoadhesive properties of emulsion based vaccines constitutes an effective in vitro strategy for selecting NE candidates for further evaluation in vivo as mucosal adjuvants.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24320221      PMCID: PMC4031264          DOI: 10.1021/mp4005029

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  39 in total

Review 1.  Nasal vaccines.

Authors:  S S Davis
Journal:  Adv Drug Deliv Rev       Date:  2001-09-23       Impact factor: 15.470

Review 2.  Novel generations of influenza vaccines.

Authors:  George Kemble; Harry Greenberg
Journal:  Vaccine       Date:  2003-05-01       Impact factor: 3.641

Review 3.  Immunity in response to particulate antigen-delivery systems.

Authors:  Tazio Storni; Thomas M Kündig; Gabriela Senti; Pål Johansen
Journal:  Adv Drug Deliv Rev       Date:  2005-01-10       Impact factor: 15.470

4.  Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans.

Authors:  B Haneberg; R Dalseg; E Wedege; E A Høiby; I L Haugen; F Oftung; S R Andersen; L M Naess; A Aase; T E Michaelsen; J Holst
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

Review 5.  Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity.

Authors:  R M Zinkernagel; S Ehl; P Aichele; S Oehen; T Kündig; H Hengartner
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

Review 6.  Mucin biophysics.

Authors:  R Bansil; E Stanley; J T LaMont
Journal:  Annu Rev Physiol       Date:  1995       Impact factor: 19.318

7.  Evaluation in children of cold-adapted influenza B live attenuated intranasal vaccine prepared by reassortment between wild-type B/Ann Arbor/1/86 and cold-adapted B/Leningrad/14/55 viruses.

Authors:  N P Obrosova-Serova; A N Slepushkin; A P Kendal; M W Harmon; E I Burtseva; N I Bebesheva; A L Beljaev; N I Lonskaja; T E Medvedeva; A Y Egorov
Journal:  Vaccine       Date:  1990-02       Impact factor: 3.641

8.  Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

Authors:  Kent R Van Kampen; Zhongkai Shi; Peng Gao; Jianfeng Zhang; K Wade Foster; Dung-Tsa Chen; Donald Marks; Craig A Elmets; De-chu C Tang
Journal:  Vaccine       Date:  2005-01-11       Impact factor: 3.641

9.  Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly.

Authors:  J J Treanor; H R Mattison; G Dumyati; A Yinnon; S Erb; D O'Brien; R Dolin; R F Betts
Journal:  Ann Intern Med       Date:  1992-10-15       Impact factor: 25.391

10.  Nasal delivery of peptides: an in vitro cell culture model for the investigation of transport and metabolism in human nasal epithelium.

Authors:  T Kissel; U Werner
Journal:  J Control Release       Date:  1998-04-30       Impact factor: 9.776

View more
  9 in total

1.  Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.

Authors:  Jessica J O'Konek; Paul E Makidon; Jeffrey J Landers; Zhengyi Cao; Carrie-Anne Malinczak; Jessie Pannu; Jennifer Sun; Vira Bitko; Susan Ciotti; Tarek Hamouda; Zbigniew W Wojcinski; Nicholas W Lukacs; Ali Fattom; James R Baker
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.

Authors:  Mark T Orr; Elyse A Beebe; Thomas E Hudson; David Argilla; Po-Wei D Huang; Valerie A Reese; Christopher B Fox; Steven G Reed; Rhea N Coler
Journal:  Vaccine       Date:  2015-11-03       Impact factor: 3.641

3.  Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants.

Authors:  Pamela T Wong; Pascale R Leroueil; Douglas M Smith; Susan Ciotti; Anna U Bielinska; Katarzyna W Janczak; Catherine H Mullen; Jeffrey V Groom; Erin M Taylor; Crystal Passmore; Paul E Makidon; Jessica J O'Konek; Andrzej Myc; Tarek Hamouda; James R Baker
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

4.  Modified Nanoemulsions with Iron Oxide for Magnetic Resonance Imaging.

Authors:  Yongyi Fan; Rui Guo; Xiangyang Shi; Steven Allen; Zhengyi Cao; James R Baker; Su He Wang
Journal:  Nanomaterials (Basel)       Date:  2016-11-25       Impact factor: 5.076

5.  Chitosan Glutamate-Coated Niosomes: A Proposal for Nose-to-Brain Delivery.

Authors:  Federica Rinaldi; Patrizia N Hanieh; Lik King Nicholas Chan; Livia Angeloni; Daniele Passeri; Marco Rossi; Julie Tzu-Wen Wang; Anna Imbriano; Maria Carafa; Carlotta Marianecci
Journal:  Pharmaceutics       Date:  2018-03-22       Impact factor: 6.321

6.  Intranasal delivery of Clozapine using nanoemulsion-based in-situ gels: An approach for bioavailability enhancement.

Authors:  Nourhan A Abdulla; Gehan F Balata; Hanaa A El-Ghamry; Eman Gomaa
Journal:  Saudi Pharm J       Date:  2021-11-15       Impact factor: 4.330

Review 7.  Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators.

Authors:  Elke S Bergmann-Leitner; Wolfgang W Leitner
Journal:  Vaccines (Basel)       Date:  2014-04-10

8.  Silicone Oil-Based Nanoadjuvants as Candidates for a New Formulation of Intranasal Vaccines.

Authors:  Agnieszka Razim; Marcelina Pyclik; Katarzyna Pacyga; Sabina Górska; Jintao Xu; Michal A Olszewski; Andrzej Gamian; Andrzej Myc
Journal:  Vaccines (Basel)       Date:  2021-03-08

9.  A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine.

Authors:  Sonia Jangra; Jeffrey J Landers; Raveen Rathnasinghe; Jessica J O'Konek; Katarzyna W Janczak; Marilia Cascalho; Andrew A Kennedy; Andrew W Tai; James R Baker; Michael Schotsaert; Pamela T Wong
Journal:  Front Immunol       Date:  2021-09-16       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.